Journal Mobile Options
Table of Contents
Vol. 34, No. 5-6, 2012
Issue release date: December 2012
Section title: Original Paper
Cerebrovasc Dis 2012;34:400–405
(DOI:10.1159/000343504)

Utilization of Intravenous Thrombolysis in 3–4.5 Hours: Analysis of the Minnesota Stroke Registry

Tekle W.G. · Chaudhry S.A. · Hassan A.E. · Peacock J.M. · Lakshminarayan K. · Tsai A. · Luepker R. · Anderson D.C. · Qureshi A.I.
aZeenat Qureshi Stroke Research Center, University of Minnesota Medical Center, Minneapolis, Minn., and bMinnesota Department of Health, St. Paul, Minn., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 11/18/2011 1:33:11 PM
Accepted: 9/14/2012
Published online: 12/4/2012

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 1

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: http://www.karger.com/CED

Abstract

Background: The American Heart Association and the American Stroke Association recommend intravenous (IV) thrombolysis up to 4.5 h from acute ischemic stroke symptom onset based on its proven benefit in improving patient outcomes. We analyzed data from the Minnesota Stroke Registry to assess the rates of IV thrombolytic utilization and the process of care in this expanded window. Methods: We identified patients who had received IV recombinant tissue plasminogen activator (rt-PA) at any of the 19 participating hospitals from January 1, 2008 till December 31, 2010. Treatment groups were those actually treated by IV rt-PA in 0–3 h and those treated by IV rt-PA in 3–4.5 h. Duration from symptom onset to arrival in the emergency department (ED) was dichotomized to cohorts of 0–2 and 2–3.5 h. We determined the overall utilization of IV rt-PA in the expanded window and calculated door-to-needle times for the two treatment windows. We also ascertained the rates of symptomatic intracerebral hemorrhage between the two treatment groups. Results: Out of the total 519 patients who received IV rt-PA for acute ischemic stroke, 433 (83%) were treated within 0–3 h and 86 (17%) within 3–4.5 h. Of all the patients who received IV rt-PA within 3–4.5 h, 45% arrived at the ED within 2 h of symptom onset. Median door-to-needle time for the 0- to 3-hour window was 74.5 min [interquartile range (IQR) 57–90] and 54 min (IQR 43.5–70.5) for the 3- to 4.5-hour window. Based on arrival time to the ED, door-to-needle time of ≤60 min was achieved by only 31% (142/458) of patients who arrived within 0–2 h of their symptom onset compared to 61% (37/61) of those who arrived at the ED within 2–3.5 h of their symptom onset. Fifty-nine (14%) patients in the 0- to 3-hour group and 17 (20%) patients in the 3- to 4.5-hour group received a combination of IV rt-PA and endovascular treatments. Among patients with documented admission National Institutes of Health Stroke Scale scores, the values (median with IQR) were different between the 0- to 3- and the 3- to 4.5-hour group, i.e. 10 (IQR 5–18) and 7 (IQR 4–14), respectively. Conclusion: Patients who received IV rt-PA within the 3- to 4.5-hour window comprised 17% of all IV rt-PA cases treated in the Minnesota Stroke Registry hospitals after the new guidelines recommended a time window expansion. Almost half of these patients would have qualified for treatment within the 0- to 3-hour window as they presented within 0–2 h of symptom onset. Patients arriving 2–3.5 h after symptom onset received thrombolysis on average 20 min faster than patients arriving within 2 h of symptom onset.


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 11/18/2011 1:33:11 PM
Accepted: 9/14/2012
Published online: 12/4/2012

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 1

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: http://www.karger.com/CED


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S, ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–774.
  2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.
  3. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245–1251.
  4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
  5. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 h after symptom onset – the ATLANTIS study: a randomized controlled trial. JAMA 1999;282:2019–2026.
  6. Clark WM, Albers GW, Madden KP, Hamilton S: The rt-PA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke 2000;31:811–816.
  7. Maiser SJ, Georgiadis AL, Suri MF, Vazquez G, Lakshminarayan K, Qureshi AI: Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis. Int J Stroke 2011;6:25–32.
  8. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008;359:1317–1329.
  9. Wahlgren N, Ahmed N, Dávalos A, Hacke W, Millán M, Muir K, Roine RO, Toni D, Lees KR, SITS Investigators: Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303–1309.
  10. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr: Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945–2948.
  11. Shobha N, Buchan AM, Hill MD: Thrombolysis at 3–4.5 hours after acute ischemic stroke onset – evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis 2010;31:223–228.
  12. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, Parsons M, Roine RO, Toni D, Ringleb P, SITS investigators: Implementation and outcome of thrombolysis with alteplase 3–4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866–874.
  13. Pervez MA, Silva G, Masrur S, Betensky RA, Furie KL, Hidalgo R, et al: Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe. Stroke 2010;41:e18–e24.
  14. Suzuki S, Saver JL, Scott P, Jahan R, Duckwiler G, Starkman S, et al: Access to intra-arterial therapies for acute ischemic stroke: an analysis of the US population. AJNR Am J Neuroradiol 2004;25:1802–1806.
  15. Wattigney WA, Croft JB, Mensah GA, Alberts MJ, Shephard TJ, Gorelick PB, Nilasena DS, Hess DC, Walker MD, Hanley DF Jr, Shwayder P, Girgus M, Neff LJ, Williams JE, LaBarthe DR, Collins JL, Paul Coverdell National Acute Stroke Registry: Establishing data elements for the Paul Coverdell National Acute Stroke Registry: part 1: proceedings of an expert panel. Stroke 2003;34:151–156.
  16. Minnesota Stroke Registry: Case definition and case identification protocol website. http://www.mnstrokeregistry.org/documents/MSRCaseDefinitionandIdentification110113.pdf (accessed July 20, 2011).
  17. Manual – The Joint Commission. Performance Measurement (PM), IV Thrombolytic Therapy, 2009. http://www.jointcommission.org/standards_information/jcfaq.aspx?ProgramId=47 (accessed July 20, 2012).
  18. Tekle WG, Chaudhry SA, Hassan AE, Rodriguez GJ, Suri FK, Vazquez G, et al: Utilization and outcomes of intravenous thrombolysis in expanded time window (3–4.5 h) in general practice with concurrent availability of endovascular treatment. J Vasc Interv Neurol 2012;5:22–26.

    External Resources

  19. Qureshi AI, Kirmani JF, Sayed MA, Safdar A, Ahmed S, Ferguson R, Hershey LA, Qazi KJ, Buffalo Metropolitan Area and Erie County Stroke Study Group: Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 2005;64:2115–2120.
  20. Fang J, Yan W, Jiang GX, Li W, Cheng Q: Time interval between stroke onset and hospital arrival in acute ischemic stroke patients in Shanghai, China. Clin Neurol Neurosurg 2011;113:85–88.
  21. Schwamm LH, Fonarow GC: Thrombolysis 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008;359:2840, author reply 2841.